Brenda S. Furlow J.D.
Net Worth

Last updated:

What is Brenda S. Furlow J.D. net worth?

The estimated net worth of Ms. Brenda S. Furlow J.D. is at least $24,483,451 as of 8 Dec 2022. She owns shares worth $1,429,842 as insider, has earned $14,163,609 from insider trading and has received compensation worth at least $8,890,000 in Bio-Techne Corporation.

What is the salary of Brenda S. Furlow J.D.?

Ms. Brenda S. Furlow J.D. salary is $1,270,000 per year as Executive Vice President, Gen. Counsel, Sec. & Chief Compliance Officer in Bio-Techne Corporation.

How old is Brenda S. Furlow J.D.?

Ms. Brenda S. Furlow J.D. is 67 years old, born in 1958.

What stocks does Brenda S. Furlow J.D. currently own?

As insider, Ms. Brenda S. Furlow J.D. owns shares in one company:

Company Title Shares Price per share Total value
Bio-Techne Corporation (TECH) Executive Vice President, Gen. Counsel, Sec. & Chief Compliance Officer 26,092 $54.8 $1,429,842

What does Bio-Techne Corporation do?

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

TECH logo
TECH
Bio-Techne Corporation
$54.8

Brenda S. Furlow J.D. insider trading

Bio-Techne Corporation

Ms. Brenda S. Furlow J.D. has made 13 insider trades between 2018-2022, according to the Form 4 filled with the SEC.

The largest trade she's ever made was exercising 11,795 units of TECH stock on 30 Nov 2020. As of 8 Dec 2022 she still owns at least 26,092 units of TECH stock.

Transaction Date Security Shares Price per share Total value Source
Option
Stock Options (Right to Buy) 7,450 $31.26 $232,909
Sale
Common Stock 7,450 $82.12 $611,809
Option
Common Stock 7,450 $31.26 $232,909
Sale
Common Stock 800 $82.01 $65,605
Option
Common Stock 800 $31.26 $25,010
Option
Stock Options (Right to Buy) 800 $31.26 $25,010
Option
Common Stock 563 $177.32 $99,831
Option
Stock Options (Right to Buy) 563 $177.32 $99,831
Option
Restricted Stock Units 1,969 N/A N/A
Option
Common Stock 1,969 N/A N/A
Sale
Common Stock 6,871 $510.25 $3,505,900
Option
Stock Options (Right to Buy) 6,871 $108.49 $745,435
Option
Common Stock 6,871 $108.49 $745,435
Option
Common Stock 5,000 $108.49 $542,450
Sale
Common Stock 5,000 $504.87 $2,524,360
Option
Stock Options (Right to Buy) 5,000 $108.49 $542,450
Sale
Common Stock 3,538 $474.08 $1,677,309
Option
Common Stock 4,337 $116.77 $506,431
Option
Stock Options (Right to Buy) 4,337 $116.77 $506,431
Option
Common Stock 1,374 $108.49 $149,065
Option
Restricted Stock Units 1,374 $108.49 $149,065
Sale
Common Stock 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Option
Stock Options (Right to Buy) 10,000 N/A N/A
Sale
Common Stock 10,857 N/A N/A
Option
Common Stock 11,795 N/A N/A
Option
Stock Option (Right to Buy) 11,795 $106.59 $1,257,229
Option
Common Stock 11,795 $106.59 $1,257,229
Option
Stock Option (Right to Buy) 11,795 N/A N/A
Sale
Common Stock 10,857 $302.1 $3,279,867
Option
Restricted Stock Units 1,724 N/A N/A
Option
Common Stock 1,724 N/A N/A
Option
Common Stock 9,079 N/A N/A
Option
Stock Option (Right to Buy) 9,079 N/A N/A
Sale
Common Stock 9,079 $275.22 $2,498,759
Sale
Common Stock 9,079 N/A N/A
Sale
Common Stock 5,995 N/A N/A
Option
Stock Options (Right to Buy) 7,595 $101.42 $770,285
Option
Common Stock 7,595 N/A N/A
Option
Stock Options (Right to Buy) 7,595 N/A N/A
Option
Common Stock 8,000 N/A N/A
Sale
Common Stock 8,000 N/A N/A
Option
Stock Options (Right to Buy) 8,000 N/A N/A
Option
Restricted Stock Units 1,759 N/A N/A
Option
Common Stock 1,759 N/A N/A
Option
Common Stock 5,400 N/A N/A
Sale
Common Stock 5,400 N/A N/A
Option
Stock Options (Right to buy) 5,400 N/A N/A
Option
Common Stock 959 N/A N/A
Option
Restricted Stock Units 959 N/A N/A

Bio-Techne key executives

Bio-Techne Corporation executives and other stock owners filed with the SEC: